← Back

Wire · opportunities

Zilganersen approval brings new treatment approach for Alexander disease

Published

18 November 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at contemporarypediatrics.com →

◆ Verified

Fusion42 · 19 November 2026 · Fusion42 review

Zilganersen (Zanvastro) was approved by the FDA as the first disease-modifying therapy for Alexander disease, a rare progressive neurological disorder previously managed only with supportive care. The treatment targets the underlying disease process via intrathecal administration every 12 weeks and showed clinical improvements in motor function during trials.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Neurology-focused founders can now build around a new treatment paradigm for Alexander disease enabling earlier diagnosis and disease-specific therapies. Your platform must adapt to identify diverse patient symptom profiles to capture this emerging market.

◆ Coverage

1 source · 18 Nov 2026

◆ Related on Wire

◆ Topics

Medtechrare-diseasedisease-modifying-therapyFDA-approvalneurologyAlexander-disease